Immuno-Oncology

Pembrolizumab (Keytruda) extended overall survival versus docetaxel in the phase II/III KEYNOTE-010 trial.

Proinflammatory cytokines were elevated in patients with melanoma undergoing the combination treatment of radiation therapy and the systemic anti–CTLA-4 immunotherapy, ipilimumab.

Abnormal thyroid function tests were reported in up to 15% of patients treated with the PD-1 inhibitor pembrolizumab.

Talimogene laherparepvec has received a positive recommendation from the CHMP, which suggests that the treatment should gain European approval for patients with advanced melanoma.

Diane Reidy Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy agents in the treatment of patients with neuroendocrine carcinoma.

Pamela L. Kunz, MD, assistant professor of Medicine (Oncology), Stanford University School of Medicine, discusses the potential of immunotherapy in the treatment of patients with neuroendocrine tumors (NETs).

Dr. Ben Creelan, discusses the impact of the expanded approval of nivolumab in NSCLC and how the drug compares with pembrolizumab.

Sylvia Adams, MD, explains the potential of TILs, as well as other biomarkers, including PD-1/PD-L1, in TNBC and other breast cancer types.

Raffit Hassan, MD, Co-Chief Thoracic and Gastrointestinal Oncology Branch, Senior Investigator Head, Thoracic and Solid Tumor Immunotherapy Section at the Center for Cancer Research, National Cancer Institute, discusses a recent phase IB trial investigating avelumab in unresectable mesothelioma.

Acting 3 months ahead of schedule, the FDA approved nivolumab for patients with nonsquamous non–small cell lung cancer previously treated with platinum-based chemotherapy.

Andrea B. Apolo, MD, explains the challenges that still remain regarding toxicity and future combination therapies with avelumab, and the potential of checkpoint inhibition in urothelial carcinoma going forward.

Encouraging findings and regulatory milestones have recently been announced for the PD-1 inhibitor pembrolizumab and the PD-L1 inhibitor avelumab as treatments for patients with metastatic Merkel cell carcinoma.

Naiyer A. Rizvi, MD, discusses the future outlook for PD-1/PD-L1 checkpoint agents in non-small cell lung cancer and the potential for immunotherapy combinations.